NuVasive to Attend 40th Annual JP Morgan Healthcare Conference


SAN DIEGO, December 28, 2021 / PRNewswire / – NuVasive, Inc., (NASDAQ: NUVA), the leader in spine technology innovation focused on transforming spine surgery with procedurally integrated and minimally disruptive solutions, announced today as the general manager Chris barry will be virtually present at 40e JP Morgan Healthcare Annual Conference on Wednesday, January 12, 2022 at 12:00 p.m. (Pacific time) / 3:00 p.m. ET.

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website After the live webcast, a replay of the presentation will remain available on the website for 30 days.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The less invasive surgical solutions integrated into the company’s procedures are designed to provide reproducible and clinically proven results. The Company’s comprehensive procedure portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, surgical planning software, navigation and imaging solutions, adjustable implant systems magnetically for the spine and orthopedics, and intraoperative neuromonitoring technologies and service offerings. With over $ 1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit

Forward-looking statements
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if not materialize or do not prove to be correct, could cause the results of NuVasive to differ materially from historical results or from those expressed or implied by these forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, the risks associated with the acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product improvements, clinical and statistical verification of the benefits obtained through the use of NuVasive products, the company’s ability to properly manage inventory as it continues to launch new products, its ability recruiting and retaining management and key personnel, and other risks and uncertainties described in press releases and filings with the Securities and Exchange Commission. NuVasive’s public documents with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it was made.

Cision View original content to download multimedia:

SOURCE NuVasive, Inc.


About Author

Comments are closed.